Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast

Journal of Steroid Biochemistry and Molecular Biology

Volumn 114, Issue 1-2, 2009, Pages 68-71

  Miki, Yasuhiro ^a   Suzuki, Takashi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen; Breast carcinoma; DCIS; Estrogen; Intracrinology

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN SULFOTRANSFERASE; ESTRONE SULFATE; STEROID 5ALPHA REDUCTASE; STERYL SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE;

ANDROGEN SYNTHESIS; ARTICLE; BREAST; BREAST CARCINOMA; ESTROGEN SYNTHESIS; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TISSUE LEVEL;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL; ESTROGENS; FEMALE; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; STERYL-SULFATASE; SULFOTRANSFERASES; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 62949150115     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.12.021     Document Type: Article

References (48)

1. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Tract (2003), IARC Press, Lyon
2. Boughey J.C., Gonzalez R.J., Bonner E., and Kuerer H.M. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 12 (2007) 1276-1287
3. Skinner K.A., and Silverstein M.J. The management of ductal carcinoma in situ of the breast. Endocr. Relat. Cancer 8 (2001) 33-45
4. Moriya T., Hirakawa H., Suzuki T., Sasano H., and Ohuchi N. Ductal carcinoma in situ and related lesions of the breast: recent advances in pathology practice. Breast Cancer 11 (2004) 325-333
5. London S.J., Connolly J.L., Schnitt S.J., and Colditz G.A. A prospective study of benign breast disease and the risk of breast cancer. JAMA 267 (1992) 941-944
6. Sasano H., Suzuki T., Nakata T., and Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 13 (2006) 129-136
7. Sasano H., and Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 19 (1998) 593-607
8. Brueggemeier R.W., Hackett J.C., and Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26 (2005) 331-345
9. Osborne C., and Tripathy D. Aromatase inhibitors: rationale and use in breast cancer. Annu. Rev. Med. 56 (2005) 103-116
10. Skliris G.P., Parkes A.T., Limer J.L., Burdall S.E., Carder P.J., and Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J. Pathol. 197 (2002) 155-162
11. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lønning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., Bliss J.M., and van de Velde C. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350 (2004) 1081-1092
12. Thomas J., Hanby A., Pinder S., Ellis I., Macartney J., Clements K., Lawrence G., and Bishop H. Sloane Project Steering Group. Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. Breast J. 14 (2008) 33-38
13. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., and Morales A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123 (2005) 21-27
14. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17 (1999) 1474-1481
15. Wiechmann L., and Kuerer H.M. The molecular journey from ductal carcinoma in situ to invasive breast cancer. Cancer 112 (2008) 2130-2142
16. Allred D.C., Bryant J., Land S., Paik S., Fisher E., Julian T., Margolese R., Smith R., Mamounas T., Osborne C.K., Fisher B., and Wolmark N. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res. Treat. 76 (2002) S36
17. Meijnen P., Peterse J.L., Antonini N., Rutgers E.J., and van de Vijver M.J. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br. J. Cancer 15 (2008) 137-142
18. Esslimani-Sahla M., Kramar A., Simony-Lafontaine J., Warner M., Gustafsson J.A., and Rochefort H. Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin. Cancer Res. 11 (2005) 3170-3174
19. Kuenen-Boumeester V., Van der Kwast T.H., van Putten W.L., Claassen C., van Ooijen B., and Henzen-Logmans S.C. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int. J. Cancer 52 (1992) 581-584
20. Isola J.J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170 (1993) 31-35
21. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., and Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120 (2003) 725-731
22. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax S.F., Weybora W., Ratschek M., Tavassoli F.A., and Denk H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98 (2003) 703-711
23. Gonzalez L.O., Corte M.D., Vazquez J., Junquera S., Sanchez R., Alvarez A.C., Rodriguez J.C., Lamelas M.L., and Vizoso F.J. Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 28 (2008) 149
24. Bryan R.M., Mercer R.J., Bennett R.C., Rennie G.C., Lie T.H., and Morgan F.J. Androgen receptors in breast cancer. Cancer 54 (1984) 2436-2440
25. Conde I., Alfaro J.M., Fraile B., Ruíz A., Paniagua R., and Arenas M.I. DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha ER-beta and androgen receptor status. Breast cancer Res. 6 (2004) R140-148
26. Hanley K., Wang J., Bourne P., Yang Q., Gao A.C., Lyman G., and Tang P. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum. Pathol. 39 (2008) 386-392
27. Vottero A., Stratalis C.A., Ghizzoni L., Longui C.A., Karl M., and Chrousos G.P. Androgen receptor-mediated hypersensitivity to androgen in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. J. Clin. Endocrinol. Metab. 84 (1999) 1091-1095
28. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., and Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J. Soc. Gynecol. Invest. 12 (2005) 135-141
29. Nicolás Díaz-Chico B., Germán Rodríguez F., González A., Ramírez R., Bilbao C., Cabrera de León A., Aguirre Jaime A., Chirino R., Navarro D., and Díaz-Chico J.C. Androgens and androgen receptors in breast cancer. J. Steroid Biochem. Mol. Biol. 105 (2007) 1-15
30. Kasami M., Gobbi H., Dupont W.D., Simpson J.F., Page D.L., and Vnencak-Jones C.L. Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. Breast 9 (2000) 23-27
31. Suzuki T., Moriya T., Ariga N., Kaneko C., Kanazawa M., and Sasano H. 17β-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br. J. Cancer 82 (2000) 518-523
32. Ariga N., Moriya T., Suzuki T., Kimura M., Ohuchi N., Satomi S., and Sasano H. 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Res. 20 (2000) 1101-1108
33. Sasano H., Frost A.R., Saitoh R., Harada N., Poutanen M., Vihko R., Bulun S.E., Silverberg S.G., and Nagura H. Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 81 (1996) 4042-4046
34. Poutanen M., Isomaa V., Lehto V.P., and Vihko R. Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int. J. Cancer 50 (1992) 386-390
35. Ruder H.J., Loriaux L., and Lipsett M.B. Estrone sulfate: production rate and metabolism in man. J. Clin. Invest. 51 (1972) 1020-1033
36. Samojlik E., Santen R.J., and Worgul T.J. Plasma estrone sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma. Steroids 39 (1982) 497-507
37. Suzuki T., Nakata T., Miki Y., Kaneko C., Moriya T., Ishida T., Akinaga S., Hirakawa H., Kimura M., and Sasano H. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 63 (2003) 2762-2770
38. Miki Y., Nakata T., Suzuki T., Darnel A.D., Moriya T., Kaneko C., Hidaka K., Shiotsu Y., Kusaka H., and Sasano H. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J. Clin. Endocrinol. Metab. 87 (2002) 5760-5768
39. Saeki T., Takashima S., Sasaki H., Hanai N., and Salomon D.S. Localization of estrone sulfatase in human breast carcinomas. Breast Cancer 6 (1999) 331-337
40. Yamamoto Y., Yamashita J., Toi M., Muta M., Nagai S., Hanai N., Furuya A., Osawa Y., Saji S., and Ogawa M. Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. Oncol. Rep. 10 (2003) 791-796
41. Shibuya R., Suzuki T., Miki Y., Yoshida K., Moriya T., Ono K., Akahira J., Ishida T., Hirakawa H., Evans D.B., and Sasano H. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr. Relat. Cancer 15 (2008) 113-124
42. Hudelist G., Wülfing P., Kersting C., Burger H., Mattsson B., Zerwenka C.K., Kubista E., Gschwantler-Kaulich D., Fink-Retter A., and Singer C.F. Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. J. Cancer Res. Clin. Oncol. 134 (2008) 67-73
43. Penning T.M., Steckelbroeck S., Bauman D.R., Miller M.W., Jin Y., Peehl D.M., Fung K.M., and Lin H.K. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell. Endocrinol. 248 (2006) 182-191
44. Luu-The V., Dufort I., Pelletier G., and Labrie F. Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol. Cell. Endocrinol. 171 (2001) 77-82
45. Suzuki T., Darnel A.D., Akahira J.-I., Ariga N., Ogawa S., Kaneko C., Takeyama J., Moriya T., and Sasano H. 5α-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. J. Clin. Endocrinol. Metab. 86 (2001) 2250-2257
46. Russell D.W., and Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev. Biochem. 63 (1994) 25-61
47. Suzuki T., Miki Y., Moriya T., Akahira J., Ishida T., Hirakawa H., Yamaguchi Y., Hayashi S., and Sasano H. 5α-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int. J. Cancer 120 (2007) 285-291
48. Santner S.J., Feil P.D., and Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59 (1984) 29-33